Aytu BioPharma, Inc. (the “Company” or “Aytu”) (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its second quarter of fiscal 2024 for the period ended December 31, 2023, after the market close on Wednesday, February 14, 2024.
DENVER, CO / ACCESSWIRE / February 7, 2024 / Aytu BioPharma, Inc. (the “Company” or “Aytu”) (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its second quarter of fiscal 2024 for the period ended December 31, 2023, after the market close on Wednesday, February 14, 2024. The Company has scheduled a conference call and webcast that same day, Wednesday, February 14, 2024, at 4:30 p.m. Eastern time, to review the results followed by a question and answer section.
Conference Call Details
Date and Time: Wednesday, February 14, 2024, at 4:30 p.m. Eastern time
Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for U.S. callers or +1 (973) 528-0011 for international callers and using the participant access code 566278.
Webcast Information: The webcast will be accessible live and archived at the following link,
https://www.webcaster4.com/Webcast/Page/2142/49729 and on the Company’s website, within the Investors section under Events & Presentations, at aytubio.com, and may be discontinued at any time.
Replay: A teleconference replay of the call will be available until February 28, 2024 at (877) 481-4010 for U.S. callers or +1 (919) 882-2331 for international callers and using replay access code 49729.
About Aytu BioPharma, Inc.
Aytu BioPharma is a pharmaceutical company focused on commercializing novel therapeutics. The Company’s prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com.
Contacts for Investors:
Mark Oki, Chief Financial Officer
Aytu BioPharma, Inc.
moki@aytubio.com
Robert Blum or Roger Weiss
Lytham Partners
aytu@lythampartners.com
SOURCE: Aytu BioPharma, Inc.
View the original press release on accesswire.com
